Sellas Life Sciences announces exercise of warrants for $23.6M in proceeds

SELLAS Life Sciences (SLS) announced the immediate exercise of warrants, previously issued in January 2025, to purchase up to 19,685,040 shares of its common stock for gross cash proceeds of approximately $23.6M In consideration for the immediate exercise in full of the warrants issued in January 2025, the investor will receive, in a private placement, new unregistered warrants to purchase up to 19,685,040 shares of its common stock at an exercise price of $1.88, will be exercisable immediately and will expire five years and six months from the date of issuance. The closing of this transaction is expected to occur on or about September 12, 2025, subject to satisfaction of customary closing conditions. A.G.P./Alliance Global Partners and Maxim Group acted as the financial advisors in connection with the transaction.